Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Comparison of Insulin Detemir NN729 vs NN304 in Type 1 Diabetes
NCT00447382Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2007
- Primary completion
- Jul 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of insulin detemir in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies at 52 weeks. Started Mar 2007; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00447382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447382.